Diabetes and glycaemic-control evidence summaries covering HbA1c, glucose monitoring, medication comparisons, hypoglycaemia, patient-reported outcomes, and clinical interpretation.
A single-centre randomised trial of 200 women found metformin matched insulin for glycaemic control in gestational diabetes, with some neonatal outcomes favouring metformin. PICO summary and expert commentary.
A three-arm randomized trial in Texans with uncontrolled type 2 diabetes found that all three self-paced virtual and technology-based self-management programs significantly reduced A1c, with no in-person comparator. PICO summary and expert commentary.
A single-centre Shanghai RCT found a family-support self-management programme raised self-management behaviour scores in type 2 diabetes, while HbA1c and other biochemical markers did not improve significantly. PICO summary and expert commentary.
DIAMONDS is a published protocol for a randomised trial testing a supported diabetes self-management programme in adults with type 2 diabetes and severe mental illness; no results are reported yet. PICO summary and expert commentary.
A single-arm extension found HbA1c was sustained over 30 weeks in adults with type 1 diabetes who switched to inhaled technosphere insulin plus degludec. PICO summary and expert commentary.
A 13-week single-arm switch study tested inhaled technosphere insulin plus degludec against participants' own baseline in 49 adults with type 1 diabetes. PICO summary and expert commentary.
An open-label trial found that pioglitazone/metformin plus dapagliflozin did not beat basal insulin/metformin on its primary glycaemic endpoint, with secondary metabolic signals favouring the oral regimen. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China examining whether the glycaemic efficacy of once-weekly semaglutide versus sitagliptin in adults with type 2 diabetes varies by baseline characteristics. PICO summary and expert commentary.
A manufacturer-sponsored 28-week RCT used mixed-meal testing to compare how tirzepatide and semaglutide improve glucose control in type 2 diabetes. PICO summary and expert commentary.
PIONEER 12 was a 26-week double-blind Phase IIIa trial showing all three doses of once-daily oral semaglutide lowered HbA1c and body weight more than sitagliptin 100 mg in a predominantly Chinese type 2 diabetes population. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
